Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Recruiting 5Not yet recruiting 5Unknown 3Terminated 3Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 21Breast 5Thoracic 3Other solid neoplasm 3Head & Neck 3Lymphoid 2Tumor-Agnostic 1Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Immune Checkpoint Inhibitors × Breast × Clear all
NCT07317778 2026-01-05

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
249 enrolled
Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT05806385 2025-09-09

LOGIC

Texas Tech University Health Sciences Center

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06842472 2025-02-24

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
70 enrolled
Breast

Breast Neoplasms

NCT06733233 2024-12-13

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Guangzhou Women and Children's Medical Center

Phase 2 Not yet recruiting
23 enrolled
Breast

Breast Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡